A nationwide Optum claims cohort (413,450 PMOS; 2,067,250 controls) showed composite ASCVD incidence 4.52 vs 0.78 per 1000 person-years and an adjusted HR of 4.40. Coronary artery disease, ...
Deepak Bhatt, MD, MPH, MBA, discusses how new evidence, prevention definitions, and imaging advances are reshaping how PCSK9 ...
Paul Hahn, MD, says access and reimbursement, not innovation, are retina care’s biggest barriers and outlines where the field is headed next. The biggest obstacle to translating retina’s technology ...
Modeling of 82 brand drugs with ≥$100 million Medicaid spend found net prices exceeded at least one international reference ...
A 12-week prospective cohort enrolled 73 patients with guideline-based asthma or COPD and no speech-affecting comorbidities, ...
The FDA approved enlicitide (Lipfendra; Merck), the first oral PCSK9 inhibitor for lowering low-density lipoprotein ...
Propensity-matched comparisons across 11 Kaiser Permanente Southern California service areas showed similar 30-day composite ...
A rebate-driven formulary model allegedly incentivized higher insulin list prices, affecting three PBMs controlling roughly ...
This study examines how key players in managed care drive postacute home health referrals, identifying tensions, limited ...
AHSCT resets the immune system in highly active RRMS after high-efficacy drugs fail, delivering higher NEDA, fewer relapses, and durable function gains. When high-efficacy drugs stop holding relapsing ...
Restricting step-up dosing and acute triage to a defined T-cell engaging team improves safety and consistency, with patients transitioning back to primary oncologists after stabilization. Standardized ...
Facility charges exceeded professional fees in variability for 25 of 26 services, with median facility interquartile ratios 2.56 versus 1.78 for professional prices ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results